Enzalutamide 100 mg | 100.00%
TargetMol
Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells).
More Information Supplier PageEnzalutamide
Search Results
Obatoclax Mesylate 100 mg | Purity Not Available
TargetMol
Obatoclax is a Bcl-2 antagonist (Ki: 0.22 μM) and can induce apoptosis with up-regulation of Bim, induced cytochrome c release, and activation of caspase-3.
More Information Supplier PageObatoclax Mesylate
GSK-J1 5 mg | 99.67%
TargetMol
GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
More Information Supplier PageGSK-J1
GSK-J1 100 mg | 99.67%
TargetMol
GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
More Information Supplier PageGSK-J1
Chloroquine phosphate 200 mg | 99.64%
TargetMol
Chloroquine phosphate (Aralen phosphate) is an aminoquinoline antimalarial and also is widely used as an autophagy inhibitor. Chloroquine also is an inhibitor of toll-like receptors (TLRs).
More Information Supplier PageChloroquine phosphate
Pioglitazone hydrochloride 100 mg | 99.66%
TargetMol
Pioglitazone Hydrochloride is the hydrochloride salt of an orally-active thiazolidinedione with antidiabetic properties and potential antineoplastic activity.
More Information Supplier PagePioglitazone hydrochloride
Pexmetinib 5 mg | 99.07%
TargetMol
Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
More Information Supplier PagePexmetinib
Pexmetinib 25 mg | 99.07%
TargetMol
Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
More Information Supplier PagePexmetinib
Pexmetinib 10 mg | 99.07%
TargetMol
Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
More Information Supplier PagePexmetinib
Pexmetinib 100 mg | 99.07%
TargetMol
Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
More Information Supplier PagePexmetinib
